A non-invasive respiratory support package comprising of two devices to treat COVID-19 significantly minimizes aerosolized spread in hospitals and aims to free-up critical Intensive Care Unit (ICU) resources for those with more severe symptoms.

Both the devices from Subsalve USA (North Kingstown, RI, USA) and Nanotronics Health (New York, NY, USA) have been granted Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to treat COVID-19. The first device, Subsalve Oxygen Treatment Hood from Subsalve USA, is a patient interface intended for helmet-based Non-Invasive Positive Pressure Ventilation, according to clinician-established protocols to treat Acute Respiratory Distress Symptoms resulting from COVID-19. The device is for use with adult patients only in ICU settings and is a mode of non-invasive ventilation (NIV) that provides increased patient airway pressure, delivery of therapeutic oxygen.

The second device, nHale from Nanotronics Health, is a bi-level positive air pressure (BiPAP) device to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease. It is a non-invasive ventilator designed to be used in non-life-threatening situations, for spontaneously breathing patients, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols. The machine is for use in traditional healthcare facilities (e.g., hospitals, assisted living facilities, nursing homes) as well as spaces converted for the care of large numbers of COVID-19 patients (e.g., convention centers, university dormitories, motels, etc.).

“The system is fantastic and already saved and is continuing to save lives in Bolivia,” said primary care physician Dr. Cesar Vargas on the front lines of COVID-19 treatment in Bolivia. “Our physicians are more familiar and eager to use the device and share the benefits with other hospitals."

http://www.gzjiayumed.com/en/index.asp